Identify the toxicological mode of action/adverse outcome pathway
Concept Life Sciences has an extensive track record in the design, performance and interpretation of preclinical investigative mechanistic, exploratory and predictive (discovery) toxicology programs.
These programs are typically intended to identify the toxicological mode of action/adverse outcome pathway affected by the compound in question and are supported by a highly experienced scientific team with extensive academic and industry experience.
Our teams build and deploy novel in vitro predictive and mechanistic assays for screening of candidate compounds to provide comparative data on toxicological risk. This data can be used to drive further chemistry and compound development.
Through an understanding of mechanistic toxicology at the early research stage, we can generate information that informs molecule design, candidate selection and translational risk assessment and identifies any potential safety alert.
We also provide expertise and consultancy services to further investigate findings and guide project teams during lead optimization and early development phases in pharmaceutical drug development.
Toxicology is supported by our DMPK and Bioanalytical departments.
- Investigative mechanistic toxicology
- Predictive, exploratory and discovery toxicology
- Hepatocyte toxicity (DILI, metabolism, across species)
- Neurodevelopmental toxicity
- Mitochondrial toxicity
- Consultancy services (safety reviews; lead optimization strategies)